Evotec SE (EVO)
NASDAQ: EVO · Real-Time Price · USD
5.30
+0.15 (2.91%)
At close: Nov 20, 2024, 4:00 PM
5.19
-0.11 (-2.08%)
Pre-market: Nov 21, 2024, 7:06 AM EST
Evotec SE Revenue
Evotec SE had revenue of 184.89M EUR in the quarter ending September 30, 2024, a decrease of -5.80%. This brings the company's revenue in the last twelve months to 777.05M, down -5.33% year-over-year. In the year 2023, Evotec SE had annual revenue of 781.43M with 3.99% growth.
Revenue (ttm)
777.05M EUR
Revenue Growth
-5.33%
P/S Ratio
n/a
Revenue / Employee
153,537 EUR
Employees
5,061
Market Cap
1.85B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 781.43M | 29.98M | 3.99% |
| Dec 31, 2022 | 751.45M | 133.41M | 21.59% |
| Dec 31, 2021 | 618.03M | 117.11M | 23.38% |
| Dec 31, 2020 | 500.92M | 54.49M | 12.20% |
| Dec 31, 2019 | 446.44M | 71.03M | 18.92% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Astrana Health | 1.72B |
| Addus HomeCare | 1.13B |
| Supernus Pharmaceuticals | 651.97M |
| NeoGenomics | 644.12M |
| Beam Therapeutics | 349.64M |
| Mirum Pharmaceuticals | 307.03M |
| GeneDx Holdings | 267.23M |
| Ligand Pharmaceuticals | 152.42M |
EVO News
- 3 days ago - Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec - PRNewsWire
- 5 days ago - Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion - Benzinga
- 6 days ago - Comment on Media Report - Accesswire
- 6 days ago - Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction - PRNewsWire
- 6 days ago - Halozyme weighing buyout of drugmaker Evotec, Bloomberg News reports - Reuters
- 9 days ago - Private Equity Triton Partners Takes Around 10% Stake In Evotec, Reportedly Mulls Potential Takeover Deal - Benzinga
- 14 days ago - Evotec SE (EVO) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 15 days ago - Evotec SE Reports 9M 2024 Results: Strategic Progress and Successful Expansion Amid Challenging Market Conditions - Accesswire